

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**PASSING OF CONSISTENCY EVALUATION
FOR THE GROUP'S "ENALAPRIL MALEATE TABLETS"**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “Enalapril Maleate Tablets (10mg)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has been granted approval by the National Medical Products Administration of the People’s Republic of China for passing the consistency of quality and efficacy evaluation of generic drugs (the “**Consistency Evaluation**”).

Enalapril is an angiotensin-converting enzyme inhibitor, mainly used for the treatment of essential hypertension of different stages, renovascular hypertension and heart failure of different severity. It can increase the survival rate, delay the progression of heart failure and decrease hospitalization due to heart failure for patients with symptomatic heart failure. In addition, it can prevent symptomatic heart failure and coronary artery ischemia event for patients with left ventricular dysfunction.

Enalapril Maleate Tablets is one of the key products of the Group for the treatment of hypertension, being one of the first three products of this type passing the Consistency Evaluation in China. Passing of the Consistency Evaluation indicates the consistency of the Product with the originator drug in terms of quality and efficacy, providing a medication option of good quality and competitive price for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 1 November 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

** For identification purposes only*